Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » Roche Nabs CE Mark for PIK3CA Test for Breast Cancer

Roche Nabs CE Mark for PIK3CA Test for Breast Cancer

Dec 15, 2020
|
staff reporter

NEW YORK – Roche announced Tuesday it has received CE marking for its Cobas PIK3CA Mutation test for identifying patients with metastatic breast cancer who might benefit the most from phosphoinositide 3-kinase (PI3K) targeted therapy. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Boosting Viral Surveillance

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

California Strain

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

Nucleic Acids Research Studies on Pan-Cancer MiRNA Biogenesis Mutations, Skeletal Methylation, More

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

Lander Nominated for Science Advisor

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

What's Popular?

In Regulatory News & FDA Approvals

  1. Bio-Rad, United Biomedical Get FDA Emergency Use Authorizations for Coronavirus Tests

  2. MiRxes Receives CE Mark, Singapore Regulatory Approval for Multiplex SARS-CoV-2, Flu Test

  3. FDA Grants Emergency Use Authorization for SML Genetree Molecular Coronavirus Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.